Derisking PXS, page-3

Not sure what type of response you're after! The risk of clinical failure is similar to that of any other pharma / biotech involved in clinical research.

From a business standpoint though, PXS is in a much stronger position to where it was a number of years ago to overcome any headwinds along the way (inc a very strong cash position, a number of compounds in areas with high unmet medical needs as well as an impressive share register). After all, BVF Partners & Co understand the risk and are happy to take a big position in the company. We all have a similar choice to make...